

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF CALIFORNIA

MONTIQUENO CORBETT, DAMARIS  
LUCIANO, and ROB DOBBS,  
individually and on behalf of all others  
similarly situated,  
  
Plaintiffs,  
  
v.  
  
PHARMACARE U.S., INC.,  
  
Defendant.

Case No.: 21cv137-GPC(AGS)

**ORDER GRANTING IN PART AND  
DENYING IN PART DEFENDANT’S  
MOTION TO DISMISS AND  
DENYING DEFENDANT’S MOTION  
TO STRIKE  
[Dkt. No. 6.]**

Defendant Pharmicare U.S., Inc. filed a motion to dismiss the complaint pursuant to Federal Rule of Civil Procedure 9(b), 12(b)(1) and 12(b)(6) and motion to strike under Rule 12(f). (Dkt. No. 6.) Plaintiffs filed an opposition to which Defendant replied. (Dkt. Nos. 12, 17.) The Court finds that the matter is appropriate for decision without oral argument pursuant to Local Civ. R. 7.1(d)(1). Based on the reasoning below, the Court GRANTS in part and DENIES in part Defendant’s motion to dismiss and DENIES Defendant’s motion to strike.

**Background**

On January 25, 2021, Plaintiffs Montiqueno Corbett, Damaris Luciano and Rob Dobbs (“Plaintiffs”) filed a putative class action complaint against Defendant

1 PharmaCare U.S., Inc. (“Defendant” or “PharmaCare”) for violations of California’s  
2 consumer fraud statutes for its sale of twelve dietary supplement products (“Products”)  
3 under the name Sambucol that include elderberry.<sup>1</sup> (Dkt. No. 1, Compl. ¶ 1.) Elderberry  
4 is derived from a flowering plant called Sambucus which has become a popular dietary  
5 supplement and has recently generated \$100 million in sales in the United States. (*Id.* ¶¶  
6 2, 3.)

7 Plaintiffs allege two theories of consumer fraud: 1) an illegal products theory; and  
8 2) false and misleading labels, packaging and advertising theory as well as omissions  
9 claims. On the first theory, Plaintiffs claim that Defendant’s Products are illegal to sell  
10 and are mislabeled as dietary supplements under the Food, Drug and Cosmetic Act  
11 (“FDCA”), 21 U.S.C. § 321(ff), and the Dietary Supplement Health and Education Act,  
12 (DSHEA”) which passed in 1994 and established a new framework to govern the  
13 “composition, safety, label, manufacturing and marketing of dietary supplements” as well  
14 as California’s Sherman Law, California Health & Safety Code section 110095,  
15 California’s consumer protection laws that incorporate the FDCA (*Id.* ¶¶ 23-27, 36.)

16 A dietary supplement is a “product (other than tobacco) intended to supplement the  
17 diet” and contain one or more of the following; 1) vitamins, 2) minerals, 3) herbs or other  
18 botanicals, 4) amino acid, 5) a supplement meant to increase total dietary intake, or 6) a  
19 concentrate, metabolite, constituent, extract or combination of any of the listed  
20 ingredients. (*Id.* ¶ 26 (citing 21 U.S.C. § 321(ff)(1).) Under the DSHEA, a “new”  
21 dietary ingredient (those not used in the United States before 1994), may be used in  
22 dietary supplements but must first be submitted to the FDA prior to sale unless the  
23

---

24  
25 <sup>1</sup> The 12 Elderberry Products at issue are 1) Sambucol Black Elderberry Original Syrup, 2) Sambucol  
26 Black Elderberry Advanced Immune Syrup, 3) Sambucol Black Elderberry Sugar Free Syrup, 4)  
27 Sambucol Black Elderberry Syrup for Kids, 5) Sambucol Black Elderberry Gummies, 6) Sambucol  
28 Black Elderberry Gummies for Kids, 7) Sambucol Black Elderberry Advanced Immune Capsules, 8)  
Sambucol Black Elderberry Effervescent Tablets, 9) Sambucol Black Elderberry Chewable Tablets, 10)  
Sambucol Black Elderberry Pastilles (Throat Lozenges), 11) Sambucol Black Elderberry Daily Immune  
Drink Powder, and 12) Sambucol Black Elderberry Infant Drops. (Dkt. No. 1, Compl. ¶ 1.)

1 ingredient has been “present in the food supply as an article used for food without being  
2 chemically altered.” (*Id.* ¶¶ 28, 30 (quoting 21 U.S.C. § 350b(a)(1).) A manufacturer or  
3 distributor must provide the FDA with information that demonstrates “history of use or  
4 other evidence of safety establishing that the dietary ingredient when used under the  
5 conditions recommended or suggested in the labeling of the dietary ingredient will  
6 reasonably be expected to be safe.” (*Id.* ¶ 31 quoting 21 U.S.C. § 350b(a)(2).) After  
7 receiving information about the new dietary ingredient (“NDI”), the FDA may then  
8 determine whether the manufacturer or distributor has provided an adequate basis to  
9 conclude that the NDI is reasonably expected to be safe. (*Id.* ¶ 32.) Dietary supplements  
10 that contain undisclosed NDIs are “adulterated” for purposes of the FDCA. (*Id.* ¶ 34.)  
11 The complaint avers that Defendant did not notify the FDA with the required NDI  
12 notification for its elderberry extract. (*Id.* ¶ 33.) As such, Plaintiffs allege that  
13 Defendant’s Products are illegal to sell because the elderberry extract is adulterated and  
14 misbranded under the FDCA and California’s Sherman Law. (*Id.* ¶ 36.)

15 On their illegal products theory, Plaintiffs allege three additional violations of the  
16 FDCA. First, they contend that Defendant, by marketing the Products as “scientifically  
17 tested”, “virologist developed”, “developed by a world renowned virologist”, as well as  
18 advertising that the Products “support[] immunity” or claim “immunity support” are  
19 implied disease claims under 21 C.F.R. § 101.93(g)(2) and misbranded under 21 U.S.C. §  
20 343(r)(6). (*Id.* ¶¶ 38-42, 44 50 (citing 21 U.S.C. § 343(r)(6).) These phrases promise the  
21 Products have the ability to mitigate, treat, cure, or prevent diseases which are barred by  
22 the FDCA’s requirement that a product cannot make a claim to “diagnose, mitigate, treat,  
23 cure, or prevent a specific disease or class of diseases.” (*Id.*) Second, Plaintiffs allege  
24 the Products are misbranded under 21 U.S.C. § 352(f)(1) because the labeling fails to  
25 include adequate directions for use and violate 21 U.S.C. § 331(a) of the FDCA. (*Id.* ¶¶  
26 56-59.) Third, Plaintiffs claim that the Products are misbranded by stating the Products  
27 have “high antioxidant levels” and fail to comply with 21 C.F.R. § 101.54(g). (*Id.* ¶¶ 60-  
28 68.)

1  
2 Plaintiffs’ second theory alleges that the claim that the Products have been  
3 “scientifically tested” is misleading and deceptive because no published studies that test  
4 the Products exist and those that do exist do not contain the same elderberry extract  
5 formulation used in published studies. (*Id.* ¶¶ 69-72.) Also, “scientifically tested”  
6 improperly suggests that the products are effective in keeping consumers safe from  
7 diseases which is false. (*Id.* ¶ 73.)

8 Plaintiffs Montiqueno Corbet is a resident and citizen of San Diego, California,  
9 Damaris Luciano is a resident and citizen of Holyoke, Massachusetts, and Rob Dobbs is a  
10 resident and citizen of Florissant, Missouri. (*Id.* ¶¶ 14-16.) They all purchased certain of  
11 the Products at issue after being exposed to, saw and relied on Defendant’s materially  
12 misleading representations on the either the Products’ packaging and labeling, on  
13 advertisements on T.V. or on websites. (*Id.* ¶¶ 79-93.) When they purchased the  
14 Products, they believed they were legally sold supplements and they all claim they  
15 experienced no improvement in their health after using the Products. (*Id.* ¶¶ 80, 81, 87,  
16 88, 94, 95.)

17 Plaintiffs seek to certify a national class of “All persons in the United States who  
18 purchased the Products (the ‘National Class’) for personal use and not for resale.”<sup>2</sup> (*Id.* ¶  
19 100.) They also seek to certify a California, Massachusetts and Missouri subclass. (*Id.*)  
20 The complaint alleges claims under 1) California’s Unfair Competition Law (“UCL”),  
21 Cal. Bus. & Prof. Code section 17200 *et seq.* on behalf of a national class and the  
22 California subclass; 2) California’s False Advertising Law (“FAL”), Cal. Bus. & Prof.  
23 Code section 17500 on behalf of the California subclass; 3) California’s Consumer Legal  
24 Remedies Act (“CLRA”), Cal. Civ. Code section 1750 *et seq.* on behalf of the California  
25 subclass; 4) Massachusetts General Laws Chapter 93A, § 2 on behalf of the  
26  
27

28 <sup>2</sup> The Court notes that there is no temporal limitation on the proposed class.

1 Massachusetts subclass; 5) Missouri Merchandising Practices Act (“MMPA”), Mo. Ann.  
 2 Stat. § 407.010 *et seq.* on behalf of the Missouri subclass; 6) breach of express warranty  
 3 on behalf of a national class and the subclasses; and 7) breach of the implied warranty of  
 4 merchantability on behalf of a national class and the subclasses. (*Id.* ¶¶ 111-194.)

## 5 Discussion

### 6 A. Legal Standard on Federal Rule of Civil Procedure 12(b)(1)

7 Federal Rule of Civil Procedure (“Rule”) 12(b)(1) provides for dismissal of a  
 8 complaint for lack of subject-matter jurisdiction. Fed. R. Civ. P. 12(b)(1). “A Rule  
 9 12(b)(1) jurisdictional attack may be facial or factual.” *Safe Air for Everyone v. Meyer*,  
 10 373 F.3d 1035, 1039 (9th Cir. 2004). “In a facial attack, the challenger asserts that the  
 11 allegations contained in a complaint are insufficient on their face to invoke federal  
 12 jurisdiction.” *Id.* The Court “resolves a facial attack as it would a motion to dismiss  
 13 under Rule 12(b)(6): Accepting the plaintiff’s allegations as true and drawing all  
 14 reasonable inferences in the plaintiff’s favor, the court determines whether the allegations  
 15 are sufficient as a legal matter to invoke the court’s jurisdiction.” *Leite v. Crane Co.*, 749  
 16 F.3d 1117, 1121 (9th Cir. 2014) (citation omitted). “[I]n a factual attack,” on the other  
 17 hand, “the challenger disputes the truth of the allegations that, by themselves, would  
 18 otherwise invoke federal jurisdiction.” *Safe Air for Everyone*, 373 F.3d at 1039. “In  
 19 resolving a factual attack on jurisdiction,” the Court “may review evidence beyond the  
 20 complaint without converting the motion to dismiss into a motion for summary  
 21 judgment.” *Id.* The Court “need not presume the truthfulness of the plaintiff’s  
 22 allegations” in deciding a factual attack. *Id.* Once the defendant has moved to dismiss  
 23 for lack of subject matter jurisdiction under Rule 12(b)(1), the plaintiff bears the burden  
 24 of establishing the Court’s jurisdiction. *See Chandler v. State Farm Mut. Auto Ins. Co.*,  
 25 598 F.3d 1115, 1122 (9th Cir. 2010).

26 Here, Defendant appears to make a facial challenge to subject matter jurisdiction  
 27 relying on the allegations in the complaint.

### 28 B. Legal Standard on Federal Rule of Civil Procedure 12(b)(6)

1 Federal Rule of Civil Procedure 12(b)(6) permits dismissal for “failure to state a  
2 claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). Dismissal under Rule  
3 12(b)(6) is appropriate where the complaint lacks a cognizable legal theory or sufficient  
4 facts to support a cognizable legal theory. *See Balistreri v. Pacifica Police Dep’t.*, 901  
5 F.2d 696, 699 (9th Cir. 1990). Under Rule 8(a)(2), the plaintiff is required only to set  
6 forth a “short and plain statement of the claim showing that the pleader is entitled to  
7 relief,” and “give the defendant fair notice of what the . . . claim is and the grounds upon  
8 which it rests.” *Bell Atlantic Corp. v. Twombly*, 550 U.S. 544, 555 (2007).

9 A complaint may survive a motion to dismiss only if, taking all well pleaded  
10 factual allegations as true, it contains enough facts to “state a claim to relief that is  
11 plausible on its face.” *Ashcroft v. Iqbal*, 556 U.S. 662, 678 (2009) (quoting *Twombly*,  
12 550 U.S. at 570). “A claim has facial plausibility when the plaintiff pleads factual  
13 content that allows the court to draw the reasonable inference that the defendant is liable  
14 for the misconduct alleged.” *Id.* “Threadbare recitals of the elements of a cause of  
15 action, supported by mere conclusory statements, do not suffice.” *Id.* “In sum, for a  
16 complaint to survive a motion to dismiss, the non conclusory factual content, and  
17 reasonable inferences from that content, must be plausibly suggestive of a claim entitling  
18 the plaintiff to relief.” *Moss v. U.S. Secret Serv.*, 572 F.3d 962, 969 (9th Cir. 2009)  
19 (quotations omitted). In reviewing a Rule 12(b)(6) motion, the Court accepts as true all  
20 facts alleged in the complaint, and draws all reasonable inferences in favor of the  
21 plaintiff. *al Kidd v. Ashcroft*, 580 F.3d 949, 956 (9th Cir. 2009).

22 Where a motion to dismiss is granted, “leave to amend should be granted ‘unless  
23 the court determines that the allegation of other facts consistent with the challenged  
24 pleading could not possibly cure the deficiency.’” *DeSoto v. Yellow Freight Sys., Inc.*,  
25 957 F.2d 655, 658 (9th Cir. 1992) (quoting *Schreiber Distrib. Co. v. Serv-Well Furniture*  
26 *Co.*, 806 F.2d 1393, 1401 (9th Cir. 1986)). In other words, where leave to amend would  
27 be futile, the Court may deny leave to amend. *See Desoto*, 957 F.2d at 658; *Schreiber*,  
28 806 F.2d at 1401.



1 ///

2 **C. Legal Standard on Federal Rule of Civil Procedure 9**

3 Where a claim alleges fraud or is grounded in fraud, Rule 9(b) requires a plaintiff  
 4 to “state with particularity the circumstances constituting fraud or mistake.” Fed. R. Civ.  
 5 P. 9(b). However, “[m]alice, intent, knowledge, and other conditions of a person's mind  
 6 may be alleged generally.” *Id.* A party must set forth “the time, place, and specific  
 7 content of the false representations as well as the identities of the parties to the  
 8 misrepresentation.” *Odom v. Microsoft Corp.*, 486 F.3d 541, 553 (9th Cir. 2007)  
 9 (internal quotation marks omitted).

10 Allegations of fraud must be “specific enough to give defendants notice of the  
 11 particular misconduct which is alleged to constitute the fraud charged so that they can  
 12 defend against the charge and not just deny that they have done anything wrong.”  
 13 *Semegen v. Weidner*, 780 F.2d 727, 731 (9th Cir. 1985); *see also Cooper v. Pickett*, 137  
 14 F.3d 616, 627 (9th Cir. 1997) (noting that particularity requires plaintiff to allege the  
 15 “who, what, when, where, and how” of the alleged fraudulent conduct). In addition, the  
 16 complaint must state “what is false or misleading about a statement, and why it is false.”  
 17 *In re GlenFed, Inc. Sec. Litig.*, 42 F.3d 1541, 1548 (9th Cir. 1994) (*en banc*) superseded  
 18 by statute on other grounds, *Private Sec. Litig. Reform Act of 1995*, 15 U.S.C. § 78u–  
 19 4(b)(1), *as recognized in Ronconi v. Larkin*, 253 F.3d 423, 429 n.6 (9th Cir. 2001).

20 **D. Legal Standard on Federal Rule of Civil Procedure 12(f)**

21 Rule 12(f) provides that the court “may strike from a pleading an insufficient  
 22 defense or any redundant, immaterial, impertinent, or scandalous matter.” Fed. R. Civ. P.  
 23 12(f). “The function of a 12(f) motion to strike is to avoid the expenditure of time and  
 24 money that must arise from litigating spurious issues by dispensing with those issues  
 25 prior to trial . . . .” *Whittlestone, Inc. v. Handi-Craft Co.*, 618 F.3d 970, 973 (9th Cir.  
 26 2010) (quoting *Fantasy, Inc. v. Fogerty*, 984 F.2d 1524, 1527 (9th Cir. 1993), *rev'd on*  
 27 *other grounds* 510 U.S. 517 (1994)).

28

1 “Motions to strike are ‘generally disfavored because they are often used as  
 2 delaying tactics and because of the limited importance of pleadings in federal practice.’”  
 3 *Cortina v. Goya Foods, Inc.*, 94 F. Supp. 3d 1174, 1182 (S.D. Cal. 2015) (quoting  
 4 *Rosales v. Citibank*, 133 F. Supp. 2d 1177, 1180 (N.D. Cal. 2001)). As such, “motions to  
 5 strike should not be granted unless it is clear that the matter to be stricken could have no  
 6 possible bearing on the subject matter of the litigation.” *Colaprico v. Sun Microsystems, Inc.*,  
 7 758 F. Supp. 1335, 1339 (N.D. Cal. 1991). “Courts will not grant motions to strike  
 8 unless ‘convinced that there are no questions of fact, that any questions of law are clear  
 9 and not in dispute, and that under no set of circumstances could the claim or defense  
 10 succeed.’” *Novick v. UNUM Life Ins. Co. of America*, 570 F. Supp. 2d 1207, 1208 (C.D.  
 11 Cal. 2008) (quoting *RDF Media Ltd. v. Fox Broad. Co.*, 372 F. Supp. 2d 556, 561 (C.D.  
 12 Cal. 2005)). “When ruling on a motion to strike, this Court ‘must view the pleading  
 13 under attack in the light most favorable to the pleader.’” *Id.* (citing *RDF Media Ltd.*, 372  
 14 F. Supp. 2d at 561).

## 15 Discussion

### 16 A. Standing

17 Defendant argues that Plaintiff’s illegal products theory fails for lack of Article III  
 18 standing and statutory standing. (Dkt. No. 6-1 at 11-13.<sup>3</sup>) Plaintiffs claim they have  
 19 Article III standing to pursue their claims that Defendant’s products were not legally sold  
 20 supplements under the FDCA and DSHEA, that if they had known about the illegality of  
 21 the Products, they would not have purchased them and they suffered an injury in fact  
 22 because they lost money when they purchased the Products. (Dkt. No. 12 at 16.) As to  
 23 statutory standing, Plaintiffs merely distinguish the cases cited by Defendant. (*Id.* at 18-  
 24 19.)

---

28 <sup>3</sup> Page numbers are based on the CM/ECF pagination.



1 As a starting point, both parties conflate the legal analysis and standard of Article  
2 III standing and statutory standing under the UCL, CLRA and warranty claims.  
3 However, Article III standing and statutory standing are distinct legal analyses. *Cetacean*  
4 *Community v. Bush*, 386 F.3d 1169, 1174-75 (9th Cir. 2004) (noting distinction between  
5 constitutional and non-constitutional standing); *In re Capacitors Antitrust Litig.*, 154 F.  
6 Supp. 3d 918, 925 (2015) (“Article III standing is different from, and not to be measured  
7 by, statutory standing.”); *City of Los Angeles v. Well Fargo & Co.*, 22 F. Supp. 3d 1047,  
8 1056 (C.D. Cal. 2014) (“Statutory standing is a different inquiry from Article III  
9 standing.”). Moreover, to support its argument, Defendant merely summarily argues that  
10 Plaintiffs’ illegal products theory have been rejected by numerous courts citing to a  
11 number of cases.<sup>4</sup> (*See* Dkt. No. 6-1 at 11-13.) However, Defendant fails to conduct a  
12 legal analysis explaining what element of Article III standing or statutory standing is  
13 deficient and fails to explain why the allegations in the complaint do not support  
14 standing.

15 Therefore, the Court DENIES Defendant’s motion to dismiss the complaint for  
16 lack of standing as not legally or factually supported. Nonetheless, the Court must  
17 consider Article III standing because “[s]tanding is a threshold matter central to our  
18 subject matter jurisdiction.” *See Bates v. United Parcel Serv., Inc.*, 511 F.3d 974, 985  
19 (9th Cir. 2007).

20 Article III, Section 2 the United States Constitution requires that a plaintiff have  
21 standing to bring a claim. *See Lujan v. Defenders of Wildlife*, 504 U.S. 555, 560 (1992).

---

22  
23  
24 <sup>4</sup> In fact, the one case Defendant cites in support of Article III does not directly support it. In *Brazil*, on  
25 the issue of whether the plaintiff’s illegal products theory was deficient under Article III standing, the  
26 district court stated “it is doubtful whether Brazil’s illegal product theory is sufficient to establish  
27 causation for purposes of Article III standing” and instead conducted an analysis of standing under the  
28 UCL, FAL and CLRA. (*See* Dkt. No. 6-1 at 12-13 (citing *Brazil v. Dole Food Co., Inc.*, Case No.: 12–  
CV–01831–LHK, 2013 WL 5312418, at \*8 (N.D. Cal. Sept. 23, 2013).) This language does not provide  
decisive support of Defendant’s Article III argument. Moreover, it is noted that in *Brazil*, the defendant  
challenged Article III based on causation. *Id.*

1 “[T]he ‘irreducible constitutional minimum of [Article III] standing’” requires that “[t]he  
2 plaintiff must have (1) suffered an injury in fact, (2) that is fairly traceable to the  
3 challenged conduct of the defendant, and (3) that is likely to be redressed by a favorable  
4 judicial decision.” *Spokeo, Inc. v. Robins*, 136 S. Ct. 1540, 1547 (2016) (citing *Lujan v.*  
5 *Defs. of Wildlife*, 504 U.S. 555, 560 (1992)). “To establish injury in fact, a plaintiff must  
6 show that he or she suffered ‘an invasion of a legally protected interest’ that is ‘concrete  
7 and particularized’ and ‘actual or imminent, not conjectural or hypothetical.’” *Id.* at 1548  
8 (quoting *Lujan*, 504 U.S. at 560). The Supreme Court noted that concreteness is quite  
9 distinct from particularization. *Id.* An injury is “particularized” if it affects “the plaintiff  
10 in a personal and individual way.” *Id.* In addition, for an injury to be “concrete”, it must  
11 be “de facto,” meaning that it is “real” and not “abstract.” *Id.* However, an injury need  
12 not be “tangible” in order to be “concrete,” and intangible injuries may constitute injury  
13 in fact. *Id.* at 1549. “Economic injury is clearly a sufficient basis for standing.” *San*  
14 *Diego Cnty. Gun Rights Committee v. Reno*, 98 F.3d 1121, 1130 (9th Cir. 1996);  
15 *Debernardis v. IQ Formulations, LLC*, 942 F.3d 1076, 1084 (11th Cir. 2019) (“Economic  
16 injuries are ‘[c]ertainly’ concrete.”).

17 The plaintiff bears the burden of demonstrating the elements of Article III  
18 standing. *Spokeo, Inc.*, 136 S. Ct. at 1547. At the pleading stage, the plaintiff “must  
19 ‘clearly . . . allege facts demonstrating’ each element.” *Id.* In a class action, Article III  
20 standing is met if at least one named plaintiff satisfies the requirements. *Bates*, 511 F.3d  
21 at 985.

22 Here, the complaint alleges the three named Plaintiffs suffered an economic injury  
23 in the amount of money spent on the Products due to the sale of illegally sold and falsely  
24 advertised Products. (Dkt. No. 1, Compl. ¶¶ 84, 91, 98, 125, 134, 160, 184, 194.)  
25 Therefore, the Court concludes that Plaintiffs have alleged “an injury in fact [] that is  
26 fairly traceable to the challenged conduct”, *Spokeo*, 136 S. Ct. at 1547, and have  
27 sufficiently alleged Article III standing. *See Backus v. General Mills, Inc.*, 122 F. Supp.  
28 3d 909, 921 (N.D. Cal. 2015) (“The purchase of such an allegedly unsafe and illegal

1 product is sufficient to confer standing for an economic injury under Article III and the  
2 UCL.”); *Pirozzi v. Apple, Inc.*, 966 F. Supp. 2d 909, 917 (N.D. Cal. 2013) (“palpable  
3 economic injuries have long been recognized as sufficient to lay the basis for standing”)  
4 (quoting *Sierra Club v. Morton*, 405 U.S. 727, 733-34 (1972)). Therefore, the Court has  
5 subject matter jurisdiction over this case.

#### 6 **B. Rule 9(b)**

7 The Ninth Circuit has held that Rule 9(b) applies to state-law causes of action,  
8 including the UCL and FAL when they are grounded in fraud. *Vess v. Ciba-Geigy Corp.*,  
9 *U.S.A.*, 317 F.3d 1097, 1103 (9th Cir. 2003) (applying Rule 9(b) to section 17500 claim);  
10 *Kearns v. Ford Motor Co.*, 567 F.3d 1120, 1125 (9th Cir. 2009) (applying Rule 9(b)  
11 particularity requirement to UCL claim grounded in fraud). When a plaintiff “allege[s] a  
12 unified course of conduct and rel[ies] entirely on that course of conduct as the basis of the  
13 claim[,] . . . the claim is said to be ‘grounded in fraud’ or to ‘sound in fraud,’ and the  
14 pleading of that claim as a whole must satisfy the particularity requirement of Rule 9(b).”  
15 *Vess*, 317 F.3d at 1103-04.

16 Defendant argues that the complaint alleges a unified fraudulent course of conduct,  
17 and therefore all causes of action fail to comply with Rule 9(b) because Plaintiffs do not  
18 specifically identify what representations they relied on, where they saw each  
19 representation, when they saw each representation, and how the representations were  
20 deceptive. (Dkt. No. 6-1 at 14.) Plaintiffs respond that their UCL claim under the  
21 unlawful and unfair prongs survive because they not grounded in fraud. (Dkt. No. 12 at  
22 19-21.) Further, they contend their allegations more than meet the Rule 9(b)  
23 requirements. (*Id.*)

24 The Court questions Defendant’s assertion that Plaintiffs’ allegations concern a  
25 unified fraudulent course of conduct so that Rule 9(b) applies to all causes of action. As  
26 noted above, Plaintiffs allege two theories of liability. One is an illegal products theory,  
27 which does not appear to sound in fraud, and the second is a false or misleading  
28 advertisement claim which are fraud claims that must comply with Rule 9(b).

1           Nonetheless, the Court concludes Plaintiffs have not complied with the specificity  
2 requirement under Rule 9(b) on the fraud claims and grants Plaintiffs leave to amend.  
3 The complaint alleges that Plaintiff Corbett purchased the Sambucol Black Elderberry  
4 Capsules, Sambucol Black Elderberry Syrup Original, and Sambucol Black Elderberry  
5 Gummies from April 2018 through April 2020 on Amazon and at CVS Pharmacy. (Dkt.  
6 No. 1, Compl. ¶ 79.) Prior to purchasing these products, Corbett relied on Defendant’s  
7 materially misleading representations on the Products’ packaging and labeling, the  
8 Sambucol website, and Amazon’s website, including, among other statements,  
9 Defendant’s claims that its elderberry ingredient was developed by a virologist, has been  
10 clinically and scientifically tested, and has been used in clinical studies. (*Id.*) Corbett’s  
11 decision to purchase Defendant’s Products was based on claims that they had been  
12 clinically and scientifically tested and the Products’ ability to support her immune system  
13 and reduce cold symptoms. (*Id.* ¶ 82.)

14           Plaintiff Luciano purchased Sambucol Black Elderberry Gummies at Walgreens,  
15 more than a year ago. (*Id.* ¶ 86.) Prior to purchasing the Products, Luciano saw and  
16 relied on Defendant’s materially misleading representations on the Products’ packaging  
17 and labeling and in television commercials, including, among other statements, that the  
18 Products were clinically and scientifically tested. (*Id.*) Luciano’s decision to purchase  
19 Defendant’s Products was also based on claims that they had been clinically and  
20 scientifically tested and the Products’ ability to support her immune system and reduce  
21 cold symptoms. (*Id.* ¶ 89.)

22           Plaintiff Dobbs purchased Sambucol Black Elderberry Gummies from August  
23 2019 to April 2020 through Amazon. (*Id.* ¶ 93.) Prior to purchasing the Sambucol  
24 products, Dobbs relied on Defendant’s materially misleading representations on the  
25 Products’ packaging and labeling, television commercials, and websites including  
26 Defendant’s claims that its Elderberry ingredient were clinically and scientifically tested  
27 and had been used in clinical studies. (*Id.*) Dobbs’ decision to buy the Products was  
28 directly impacted by misleading representations that the Elderberry Products were

1 clinically and scientifically tested and the Products’ ability to support his immune system.  
2 (*Id.* ¶ 96.)

3 On the allegations for misleading statements and false advertising, the Court  
4 concludes they do not comply with Rule 9(b). First, on the “when”, Plaintiffs only allege  
5 when they purchased Defendant’s Products but fail to specify when they saw and relied  
6 on the alleged misrepresentations or misleading advertisements or labeling. Plaintiffs  
7 must identify a time period when they saw the false advertisements. *See Interserve, Inc.*  
8 *v. Fusion Garage PTE Ltd.*, No. C-095812-RS-PSG, 2011 WL 500497, at \*3 (N.D. Cal.  
9 Feb. 9, 2011) (denying a motion to dismiss where allegations concerning “the purported  
10 fraud [were] limited to a narrow window of time”); *Griffin v. Green Tree Serv., LLC*, 166  
11 F. Supp. 3d 1030, 1057 n.63 (C.D. Cal. 2015) (one-month time period was sufficient to  
12 plead the “when” of a fraudulent misrepresentation) *McCann v. Jupina, Court*, Case  
13 No.16-cv-03244-JSC, 2017 WL 1540719, at \*2 (N.D. Cal. Apr. 28, 2017) (nine month  
14 time range when misrepresentations occurred fail to satisfy Rule 9(b)); *Hirata Corp. v.*  
15 *J.B. Oxford & Co.*, 193 F.R.D. 589, 598 (S.D. Ind. 2000) (“[Plaintiff] cannot expect  
16 simply to rest on its broad assertion that the fraud occurred over a period of six  
17 months.”). Further, on the “where”, Plaintiffs must specify where they saw each of the  
18 alleged false misrepresentations. *See Stanwood v. Mary Kay, Inc.*, 941 F. Supp. 2d 1212,  
19 1220 (C.D. Cal. 2012) (finding that plaintiff failed to meet Rule 9(b) pleading standards  
20 when she failed to point to the “particular advertisements or promotional materials that  
21 she was personally exposed to”); *Goldsmith v. Allergan, Inc.*, CV 09-7088 PSG (Ex),  
22 2011 WL 2909313, (C.D. Cal. 2011) (finding that plaintiff failed to plead fraud cause of  
23 action because he failed to specify the specific television ads on which he relied).

24 Next, on the “what”, while Plaintiffs properly allege certain specific  
25 misrepresentations they relied on such as “clinically and scientifically tested”, the  
26 Products’ “ability to support her immune system and reduce cold symptoms”, the  
27 Products were “developed by a virologist” and “used in clinical studies”, they also  
28 indicate these were just examples and necessarily imply there were other statements.

1 (Dkt. No. 1, Compl. ¶¶ 79, 89, 93.) Therefore, in their amended complaint, if Plaintiffs  
2 seek to proceed on other misrepresentations not alleged, they must specify what these  
3 other misrepresentations are in order to satisfy Rule 9(b). Accordingly, because Plaintiffs  
4 has not sufficiently alleged the “what, when and where” of the alleged  
5 misrepresentations, the Court GRANTS Defendant’s motion to dismiss the fraud based  
6 claims under Rule 9(b).

7 Finally, Defendant also argues for dismissal of the consumer fraud claims based on  
8 a challenge to the “scientifically tested” label because at best they challenge the quality of  
9 Defendant’s substantiation which is barred in California. (Dkt. No. 6-1 at 16.) Plaintiff  
10 opposes arguing that the “scientifically tested” labels are false. (Dkt. No. 12 at 23.)

11 Under California Business and Professions Code section 17508, challenges to lack  
12 of substantiation are left to the Attorney General and other prosecuting authorities while  
13 private plaintiffs have the burden of proving that advertising is actually false or  
14 misleading. *Nat’l Council Against Health Fraud v. King Bio Pharm., Inc.*, 107 Cal. App.  
15 4th 1336, 1344–45 (2003) (“private plaintiffs are not authorized to demand substantiation  
16 for advertising claims”). Therefore, “[c]laims that rest on a lack of substantiation, instead  
17 of provable falsehood, are not cognizable under the California consumer protection  
18 laws.” *Bronson v. Johnson & Johnson, Inc.*, No. C 12-04184 CRB, 2013 WL 1629191,  
19 at \*8 (N.D. Cal. Apr. 16, 2013). The holding in *King Bio* was reaffirmed in *Kwan* where  
20 the Ninth Circuit held that “California law does not provide for a private cause of action  
21 to enforce the substantiation requirements of California’s unfair competition and  
22 consumer protection laws.” *Kwan v. SanMedica Int’l*, 854 F.3d 1088, 1091 (9th Cir.  
23 2016). In order to allege a consumer fraud claim, a private plaintiff must establish the  
24 claims are false or misleading by citing to “testing, scientific literature, or anecdotal  
25 evidence.” *Id.* at 1097 (quoting *King Bio*, 107 Cal. App. 4th at 1348).

26 A claim can survive a lack of substantiation challenge by, for example, alleging  
27 studies showing that a defendant’s statement is false. *In re Clorox Consumer Litig.*, 894  
28 F. Supp. 2d 1224, 1232-33 (N.D. Cal. 2012) (denying defendant’s motion to dismiss on a



1 lack of substantiation challenge where the plaintiffs alleged two scientific studies directly  
2 contradicted the defendant's advertising). Moreover, “Plaintiff could allege that one or  
3 more of the authorities alluded to actually studied or tested the [defendant’s product] and  
4 found that it does not [deliver the promised result], or that Plaintiff herself did not  
5 experience such [a result] when using the product, or that a study exists somewhere  
6 demonstrating that [the result] is categorically impossible to achieve [ ]” *Kwan*, 854 F.3d  
7 at 1091.

8 Here, the complaint alleges that the Products’ labels state that they have been  
9 “scientifically tested” but there are no published studies that test the Products and  
10 therefore, they have not been scientifically tested. (Dkt. No. 1, Compl. ¶¶ 69, 71.)  
11 Moreover, clinical studies of Defendant’s proprietary extract have not conclusively  
12 established that the Products are in fact effective, making the “scientific testing”  
13 representation misleading. (*Id.* ¶ 74.)

14 A claim that the product has not been scientifically tested or clinical studies have  
15 not conclusively established that Defendant’s Products are effective must be dismissed  
16 for lack of substantiation. *See Kwan*, 854 F.3d at 1096 (falsely implying health benefits  
17 were clinically proven by scientific proof by label “clinically tested” and claim that  
18 “growth hormone levels are associated with certain health benefits” falsely implied  
19 product was based on scientific proof were summary and did not demonstrate falsehood  
20 of the claims); *Engel v. Novex Biotech, LLC*, 689 Fed. Appx. 510, 510–11 (9th Cir. Apr.  
21 21, 2017) (“allegations that defendant's marketing claims are not supported by any  
22 reliable clinical trials and that a comprehensive search could not produce any publication  
23 to support claims . . . do not support a finding that the advertising claims are actually  
24 false, only that they lack substantiation.”); *Tubbs v. AdvoCare Int’l, LP*, 2017 WL  
25 4022397, at \*6 (C.D. Cal. Sept. 12, 2016) (“no genuine scientific research” to support  
26 Defendant’s advertising was impermissible lack of substantiation claim). Accordingly,  
27 the Court additionally GRANTS dismissal of the UCL, FAL and CLRA causes of action  
28 to the extent they are based on the “scientifically tested” claims.

1 ///

2 ///

3 **C. Breach of the Implied Warranty of Merchantability**

4 Defendant argues that the implied warranty claim fails for lack of privity. (Dkt.  
5 No. 6-1 at 16-17.) Plaintiffs respond that vertical privity is not required because they are  
6 third-party beneficiaries. (Dkt. No. 12 at 24-25.)

7 The complaint alleges that “Plaintiffs and the Class Members purchased the  
8 Elderberry Products manufactured and marketed by Defendant by and through  
9 Defendant’s authorized sellers for retail sale to consumers, or were otherwise expected to  
10 be the third-party beneficiaries of Defendant’s contracts with authorized sellers, or  
11 eventual purchasers when bought from a third party.” (Dkt. No. 1, Compl. ¶ 190.)

12 The California Commercial Code “implies a warranty of merchantability that  
13 goods ‘[a]re fit for ordinary purposes for which such goods are used.’” *Birdsong v.*  
14 *Apple, Inc.*, 590 F.3d 955, 958 (9th Cir. 2009) (quoting Cal. Com. Code § 2314(2)(c)).  
15 “Under California Commercial Code section 2314, . . . a plaintiff asserting breach of  
16 warranty claims must stand in vertical contractual privity with the defendant.” *Clemens*  
17 *v. DaimlerChrysler Corp.*, 534 F.3d 1017, 1023 (9th Cir. 2008); *All West Elecs., Inc. v.*  
18 *M–B–W, Inc.*, 64 Cal. App. 4th 717, 725 (1998) (“The general rule is that privity of  
19 contract is required in an action for breach of either express or implied warranty and that  
20 there is no privity between the original seller and a subsequent purchaser who is in no  
21 way a party to the original sale.”); *Anthony v. Kelsey–Hayes Co.*, 25 Cal. App. 3d 442,  
22 448 (1972) (“It is settled law in California that privity between the parties is a necessary  
23 element to recovery on a breach of an implied warranty of [merchantability or] fitness for  
24 the buyer’s use, with exceptions not applicable here.”). “A buyer and seller stand in  
25 privity if they are in adjoining links of the distribution chain.” *Clemens*, 534 F.3d at  
26 1023. An “end consumer” who “buys from a retailer is not in privity with a  
27 manufacturer.” *Id.*

28

1 In *Clemens*, the Ninth Circuit identified a number of specific exceptions to the  
2 privity rule such as cases when a “plaintiff relies on written labels or advertisements of a  
3 manufacturer” and other “special cases involving foodstuffs, pesticides, and  
4 pharmaceuticals, and where the end user is an employee of the purchaser.” *Id.* at 1023  
5 (citing *Burr v. Sherwin Williams Co.*, 42 Cal. 2d 682, 695-96 (1954); *Windham at Carmel*  
6 *Mountain Ranch Ass'n v. Superior Ct.*, 109 Cal. App. 4th 1162, 1169 (2003); *Fieldstone*  
7 *Co. v. Briggs Plumbing Prods., Inc.*, 54 Cal. App. 4th 357, 369 (1997); *Gottsdanker v.*  
8 *Cutter Labs.*, 182 Cal. App. 2d 602, 608 (1960)). A direct dealing exception to the  
9 privity requirement has also been recognized by the court of appeal in *U.S. Roofing, Inc.*  
10 *v. Credit Alliance Corp.* 228 Cal. App. 3d 1431, 1442 (1991). *Cardinal Health 301, Inc.*  
11 *v. Tyco Electronics Corp.*, 169 Cal. App. 4th 116, 138-39 (2008) (applying direct dealing  
12 exception). The Ninth Circuit noted that California “has painstakingly established the  
13 scope of the privity requirement under [ ] section 2314, and a federal court sitting in  
14 diversity is not free to create new exceptions to it.” *Clemens*, 534 F.3d at 1024.

15 Before and after the Ninth Circuit ruling in *Clemens*, district courts in California  
16 have been split on whether an exception to the privity requirement exists for a breach of  
17 implied warranty of merchantability claim when a plaintiff can show that he or she was a  
18 third-party beneficiary of a contract between the defendant and a third party. *Compare*  
19 *Zeiger v. WellPet LLC*, 304 F. Supp. 3d 837, 854 (N.D. Cal. 2018) (recognizing split in  
20 authority but adopting third-party beneficiary exception); *In re MyFord Touch Consumer*  
21 *Litig.*, 46 F. Supp. 3d 936, 984 (N.D. Cal. 2014) (“the Court concludes that the third-  
22 party beneficiary exception remains viable under California law.”); *In re Sony Vaio*  
23 *Computer Notebook Trackpad Litig.*, No. 09CV2109 BEN (RBB), 2010 WL 4262191, at  
24 \*3 (S.D. Cal. Oct. 28, 2010) (finding that the plaintiffs had plausibly pleaded that the  
25 exception applied when they purchased a Sony laptop from Best Buy, which they alleged  
26 was an authorized Sony retailer and service facility); *Kearney v. Hyundai Motor Am.*, No.  
27 SACV09-1298-JST MLGX, 2010 WL 8251077, at \*10 (C.D. Cal. Dec. 17, 2010) *with*  
28 *Skiathitis v. Nyko Techs., Inc.*, No. 18-3584, 2018 WL 6427360, at \*11 (C.D. Cal. Sept.

1 12, 2018) (“The applicability of the third-party beneficiary exception to retail consumers  
2 like Plaintiffs is far from settled, but the Court concludes that the best reading of  
3 California law is that the exception does not apply.”); *Xavier v. Philip Morris USA, Inc.*,  
4 787 F. Supp. 2d 1075, 1083 (N.D. Cal. 2011) (finding that the exception does not apply  
5 because “[n]o reported California decision has held that the purchase of a consumer  
6 product may dodge the privity rule by asserting that he or she is a third-party beneficiary  
7 of the distribution agreements linking the manufacturer to the retailer who ultimately  
8 made the sale”); *Anunziato v. eMachines, Inc.*, 402 F. Supp. 2d 1133, 1141 (C.D. Cal.  
9 2005) (third-party beneficiary exception does not allow a consumer who purchased a  
10 laptop from BestBuy.com to bring a breach of implied warranty claim against the laptop  
11 manufacturer).

12 It is notable that “no published decision of a California court has applied this [third  
13 party beneficiary exception] doctrine in the context of a consumer claim against a product  
14 manufacturer.” *Loomis v. Slendertone Distrib., Inc.*, 420 F. Supp. 3d 1046, 1089 (S.D.  
15 Cal. 2019) (quoting *In re Seagate Tech. LLC Litig.*, 233 F. Supp. 3d 776, 787 (N.D. Cal.  
16 2017)); see also *Xavier v. Philip Morris USA, Inc.*, 787 F. Supp. 2d 1075, 1083 (N.D. Cal.  
17 2011) (“No reported California decision has held that the purchaser of a consumer  
18 product may dodge the privity rule by asserting that he or she is a third-party beneficiary  
19 of the distribution agreements linking the manufacturer to the retailer who ultimately  
20 made the sale.”)

21 District courts that have adopted the third-party beneficiary exception theory rely  
22 on *Gilbert Fin. Corp. v. Steelform Contracting Co.*, 82 Cal. App. 3d 65, 69-70 (1978). In  
23 that case, the court of appeal reversed the trial court’s dismissal of the breach of implied  
24 warranty claim for lack of privity made against a roofing sub-contractor and held that the  
25 plaintiff could bring such action for breach of an implied warranty of fitness against the  
26 sub-contractor because he, the owner of a building who was not named in the contract,  
27 was the intended third-party beneficiary of the contract between the contractor and the  
28 roofing subcontractor. *Id.* at 69-70. The court of appeal noted that it did not have to

1 decide the privity issue because the plaintiff was a third-party beneficiary of the contract  
2 between the contractor and sub-contractor and could therefore sue for breach of the  
3 implied warranty of fitness. *Id.* at 69. *Gilbert* is specific to its facts and has limited  
4 bearing on this case. While courts are split on recognition of the third-party beneficiary  
5 exception to the privity requirement, the cases that recognize it require a plaintiff to show  
6 that he or she was a third-party beneficiary of a contract between the defendant and a  
7 third party. *In re NVIDIA GPU Litig.*, No. C 08-04312 JW, 2009 WL 4020104, at \*7  
8 (N.D. Cal. Nov. 19, 2009) (exception to the privity requirement for a breach of implied  
9 warranty of merchantability claim if a plaintiff can show that he was a third party  
10 beneficiary of a contract between the defendant and a third party); *In re Nexus 6P Prod.*  
11 *Liab. Litig.*, 293 F. Supp. 3d 888, 924 (N.D. Cal. 2018) (“Huawei concedes that the  
12 relevant states allow plaintiffs to bring implied warranty claims in the absence of privity  
13 if the plaintiff shows that he was a beneficiary to a contract between the defendant and a  
14 third party.”)

15 Here, Plaintiffs allege that they “were otherwise expected to be the third-party  
16 beneficiaries of Defendant’s contracts with authorized sellers, or eventual purchasers  
17 when bought from a third party.” (Dkt. No. 1, Compl. ¶ 190.) This allegation does not  
18 satisfy the pleading requirement for a third party beneficiary exception to the privity  
19 requirement. Accordingly, the Court GRANTS Defendant’s motion to dismiss the beach  
20 of implied warranty of merchantability claim.

#### 21 **D. Dismissal of Claims on Products Plaintiffs Never Bought**

22 Defendant next argues that Plaintiffs’ claims should be narrowed to only those  
23 Products purchased by Plaintiffs and seeks dismissal of Products not purchased by  
24 Plaintiff for lack of standing. (Dkt. No. 6-1 at 17.) Plaintiffs respond that because  
25 Defendant made identical misrepresentation concerning all Elderberry Products, they  
26 have standing under the prevailing view in the Ninth Circuit. (Dkt. No. 12 at 25-27.)

27 The prevailing view in the Ninth Circuit is to allow class action plaintiffs to bring  
28 claims for products they did not purchase “as long as the products and alleged

1 misrepresentations are substantially similar.” *Miller v. Ghirardelli Chocolate Co.*, 912 F.  
2 Supp. 2d 861, 869 (N.D. Cal. 2012) (noting that the rulings of majority of the courts have  
3 carefully analyzed the question). There must be substantial similarity between the  
4 products at issue or the alleged misrepresentations must be similar across product lines.  
5 *Id.* “[T]he critical inquiry seems to be whether there is sufficient similarity between the  
6 products purchased and not purchased.” *Astiana v. Dreyer's Grand Ice Cream, Inc.*, No.  
7 C-11-2910 EMC, 2012 WL 2990766, at \*11 (N.D. Cal. July 20, 2012); *see Anderson v.*  
8 *Jamba Juice Co.*, 888 F. Supp. 2d 1000, 1006 (N.D. Cal. 2012) (“If there is a sufficient  
9 similarity between the products, any concerns regarding material differences in the  
10 products can be addressed at the class certification stage.”).

11 In *Anderson v. Jamba Juice Co.*, the district court held that the plaintiff, who  
12 purchased several flavors of at-home smoothie kits labeled “All Natural,” had standing to  
13 bring claims on behalf of purchasers of other flavors because the products were  
14 sufficiently similar and because the “same alleged misrepresentation was on all of the  
15 smoothie kit[s] regardless of flavor.” 888 F. Supp. 2d 1000, 1006 (N.D. Cal. 2012). In  
16 contrast, in *Miller*, the court dismissed claims on the four products the plaintiff did not  
17 purchase because not only were the products different, baking chips, three drink powders,  
18 and wafers but the labeling of the products was also different. *Miller*, 912 F. Supp. 2d at  
19 870-71.

20 Here, the Products, at issue, are similar to the extent they all contain elderberry but  
21 the products come in different forms either in syrup, gummies, capsules, tablets,  
22 lozenges, powder, and drops. (Dkt. No. 1, Compl. ¶ 1.) Because Plaintiffs allege  
23 uniformity in the representation on the packaging as well as marketing, (Dkt. No. 1,  
24 Comp. ¶¶ 9, 21, 40), at this stage of the proceedings, the Court DENIES Defendant’s  
25 motion to dismiss the claims on the Products Plaintiffs did not purchase.<sup>5</sup>  
26

---

27  
28 <sup>5</sup> In the same vein, Defendant also argues that the claims on products Plaintiffs never saw are subject to dismissal. (Dkt. No. 6-1 at 17.) However, it appears that this is a variation of the argument for



1 ///

2 ///

3 **E. Motion to Dismiss and Motion to Strike Nationwide Class Allegation**

4 Defendant, relying on *Mazza v. American Honda Motor Co.*, 666 F.3d 581 (9th  
5 Cir. 2012), moves to dismiss and moves to strike the nationwide class claims.<sup>6</sup> (Dkt. No.  
6 6-1 at 18-21.) Plaintiffs respond that to rule on this issue at the motion to dismiss stage is  
7 premature because the parties have not conducted discovery to develop the facts of the  
8 case and identify differences in various state laws. (Dkt. No. 12 at 30.) Further, with  
9 discovery, Plaintiff could narrow or define the class at the class certification stage “in  
10 such a way that it makes any purported state law differences immaterial.” (*Id.*)

11 In this case, the complaint seeks to certify a nationwide class, (Dkt. No. 1, Compl.  
12 ¶ 100), and alleges a violation of the UCL as well of breach of express warranty and  
13 breach of implied warranty on behalf of the nationwide class. (Dkt. No. 1, Compl. ¶¶  
14 112, 176, 186.)

15 In *Mazza*, the Ninth Circuit held that the district court “abused its discretion in  
16 certifying a class under California law that contained class members who purchased or  
17 leased their car in different jurisdictions with materially different consumer protection  
18 laws.” *Mazza*, 666 F.3d at 590. After conducting California’s three-step governmental  
19 interest test, *id.*, it held that under “the facts and circumstance of this case,” each “class  
20 member’s consumer protection claim should be governed by the consumer protection  
21 laws of the jurisdiction in which the transaction took place.” *Id.* at 594.

22  
23  
24  
25 dismissal based on Products never bought by Plaintiffs. Thus, for the same reasons, the Court DENIES  
26 Defendant’s motion to dismiss the claims for product Plaintiffs never saw.

27 <sup>6</sup> On this issue, while Defendant presents several arguments, that is, that non-resident class members  
28 cannot pursue a claim under the California UCL, court should strike the nationwide class allegations,  
plaintiffs fail to establish the requisite elements for class certification and certification is not appropriate  
when disparate laws of multiple state must be applied, all arguments relate to dismissal of the  
nationwide class allegations.

1 Since *Mazza*, district courts are divided on whether dismissal of a nationwide class  
2 is appropriate at the motion to dismiss stage. *Compare In re Clorox Consumer*  
3 *Litigation*, 894 F. Supp. 2d 1224, 1237 (N.D. Cal. 2012) (“Since the parties have yet to  
4 develop a factual record, it is unclear whether applying different state consumer  
5 protection statutes could have a material impact on the viability of Plaintiffs claims”);  
6 *Forcellati v. Hyland’s, Inc.*, 876 F. Supp. 2d 1155, 1159 (C.D. Cal. 2012) (“[I]t would be  
7 premature to speculate about whether the difference in various states’ consumer  
8 protection laws are material in this case.”); *Zapata Fonseca v. Goya Foods Inc.*, Case No.  
9 16-CV-02559-LHK, 2016 WL 4698942, at \*3 (N.D. Cal. Sept. 8, 2016) (denying  
10 dismissal of nationwide class because *Mazza*, which was decided at the class certification  
11 stage and not on a motion to dismiss, depended heavily on a detailed choice-of-law  
12 analysis that compared how various states’ consumer protection laws applied to the facts  
13 of the plaintiffs’ claims and the defendant failed to conduct such an analysis in its motion  
14 to dismiss); *Sonner v. Schwabe N. Am., Inc.*, No. EDCV 15-01358-VAP (SPx), 2015 WL  
15 13307076, at \*8 (C.D. Cal. Nov. 18, 2015) (“A detailed choice-of-law analysis would be  
16 inappropriate” on a motion to strike); *Valencia v. Volkswagen Grp. of America Inc.*, Case  
17 No. 15-cv-00887-HSG, 2015 WL 4760707, at \*1 (N.D. Cal. Aug. 11, 2015) (“Whether  
18 California law differs from the laws of other states in a way that is material *to this*  
19 *litigation* is not a proper inquiry at the pleading stage.”) (emphasis in original) *with Glenn*  
20 *v. Hyundai Motor Am.*, SACV 15-2052 DOC (KESx), 2016 WL 3621280, at \*5 (C.D.  
21 Cal. June 24, 2016) (“The Court notes that while *Mazza* was decided at the class  
22 certification stage, the decision ‘applies generally and is instructive when addressing a  
23 motion to dismiss.’”) (quoting *Frezza v. Google, Inc.*, CV 5:12-237 RMW, 2013 WL  
24 1736788, at \*6 (N.D. Cal. Apr. 22, 2013)); *Davison v. Kia Motors America, Inc.*, No. 15-  
25 cv-0239-CJC (RNBx), 2015 WL 3970502, at \*2 (C.D. Cal. 2015) (conducting choice of  
26 law analysis at motion to dismiss). “*Mazza* did not purport to hold that nationwide  
27 classes are, as a matter of law, uncertifiable under California’s consumer protection  
28 laws.” *Forcellati*, 876 F. Supp. 2d at 1159.

1 While the *Mazza* analysis may ultimately apply to the analysis in this case as it  
2 involved a defendant in California and concerned the applicability of California's  
3 consumer fraud statutes to plaintiffs who lived outside the state, Plaintiffs should be  
4 given an opportunity through discovery to demonstrate that a nationwide class is viable at  
5 the class certification stage. Moreover, Defendant has failed to provide a sufficient  
6 choice of law analysis on California's consumer fraud statutes and breaches of express  
7 and implied warranty claims. Accordingly, the Court DENIES Defendant's motion to  
8 strike and motion to dismiss the nationwide class allegation.

9 **F. Leave to Amend**


10 In the event the Court dismisses any cause of action, Plaintiffs seek leave to  
11 amend. (Dkt. No. 12 at 20.) Where a motion to dismiss is granted, leave to amend  
12 should be granted "unless the court determines that the allegation of other facts consistent  
13 with the challenged pleading could not possibly cure the deficiency." *DeSoto*, 957 F.2d  
14 at 658 (quoting *Schreiber Distrib. Co.*, 806 F.2d at 1401). That is, where leave to amend  
15 would be futile, the Court may deny leave to amend. *See Desoto*, 957 F.2d at 658;  
16 *Schreiber*, 806 F.2d at 1401. In this case, because Plaintiff can cure the deficiencies in  
17 the complaint, the Court GRANTS Plaintiff leave to file a first amended complaint. *See*  
18 *De Soto*, 957 F.2d at 658.

19 **Conclusion**

20 Based on the above, the Court GRANTS in part and DENIES in part Defendant's  
21 motion to dismiss with leave to amend. The Court also DENIES Defendant's motion to  
22 strike. Plaintiff shall file an amended complaint within 20 days of the filed date of this  
23 order.

24 IT IS SO ORDERED.

25 Dated: June 17, 2021

26   
27 Hon. Gonzalo P. Curiel  
28 United States District Judge